All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to speak to Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
In this video, Wendy Osborne discusses the Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). She talks about the results from the phase I/II study that assesses the safety and efficacy of this bicistronic approach, which was designed to overcome CD19 escape and CAR T exhaustion.
Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
13 votes - 29 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox